Efficacy of Memantine ER on Activities of Daily Living: A Post Hoc Responder Analysis From a Randomized Trial in Patients With Moderate-to-severe Alzheimer's Disease

被引：0
|
作者：
Alva, Gustavo [1 ]
Grossberg, George [2 ]
Hendrix, Suzanne [3 ]
Ellison, Noel [3 ]
Andersen, Kristen A. [4 ]
Edwards, John [5 ]
机构：
[1] ATP Clin Res, Costa Mesa, CA USA
[2] St Louis Univ, St Louis, MO 63103 USA
[3] Pentara Corp, Salt Lake City, UT USA
[4] Prescott Med Commun Grp, Chicago, IL USA
[5] Allergan Plc, Jersey City, NJ USA
来源：
NEUROLOGY | 2017年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P3.087
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Effects of donepezil in patients with moderate-to-severe Alzheimer's disease discontinuing memantine monotherapy
    Sakka, P.
    Tsolaki, M.
    Hort, J.
    Hager, K.
    Soininen, H.
    Lopez-Pousa, S.
    Li, C.
    Schwam, E.
    EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 : 58 - 58
  • [22] Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer's disease in the Netherlands
    Hoogveldt, Bart
    Rive, Benoit
    Severens, Johan
    Maman, Khaled
    Guilhaume, Chantal
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2011, 7 : 313 - 317
  • [23] Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden
    Feldman, H
    Gauthier, S
    Hecker, J
    Vellas, B
    Emir, B
    Mastey, V
    Subbiah, P
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2003, 51 (06) : 737 - 744
  • [24] Memantine ER and Donepezil Treatment Maintains Cognitive Improvements Versus Donepezil Monotherapy: Post Hoc Analyses From a Placebo-controlled Study in Patients with Moderate-to-Severe Alzheimer's Disease
    Atri, Alireza
    Cummings, Jeffrey L.
    Hendrix, Suzanne
    Ellison, Noel
    Edwards, John
    NEUROLOGY, 2018, 90
  • [25] Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease
    Galasko, D
    Schmitt, F
    Thomas, R
    Jin, S
    Bennett, D
    Ferris, S
    JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY, 2005, 11 (04) : 446 - 453
  • [26] Efficacy of Memantine by Baseline Disease Severity: Post-hoc Analysis of Pooled Trials in Patients with Mild to Moderate Alzheimer's Disease
    Tocco, M.
    Hendrix, S.
    Miller, M. L.
    Pejovic, V.
    Graham, S. M.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2011, 59 : S124 - S124
  • [27] Efficacy and tolerability of memantine in nursing home patients with moderate-to-severe dementia of the Alzheimer's type
    Winblad, B
    Graham, S
    Lee, G
    Möbius, HJ
    McDonald, S
    INTERNATIONAL PSYCHOGERIATRICS, 2003, 15 : 259 - 260
  • [28] Efficacy and Safety of Donepezil 23 mg/Day in Patients with Moderate-to-Severe Alzheimer's Disease with Concomitant Memantine Use
    Doody, Rachelle S.
    Ramos, Harry
    Faison, Warachal
    Zou, Heng
    NEUROLOGY, 2011, 76 (09) : A619 - A620
  • [29] A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease
    Herrmann, Nathan
    Gauthier, Serge
    Boneva, Neli
    Lemming, Ole Michael
    INTERNATIONAL PSYCHOGERIATRICS, 2013, 25 (06) : 919 - 927
  • [30] Effects of memantine on behavioural symptoms in moderate-to-severe Alzheimer's disease patients: a post-marketing surveillance study
    Clerici, F.
    Vanacore, N.
    Elia, A.
    Alegiani, S. Spila
    Pomati, S.
    Da Cas, R.
    Raschetti, R.
    Mariani, C.
    JOURNAL OF NEUROLOGY, 2009, 256 : S73 - S73
12345